Categories AlphaGraphs, Earnings, Health Care, LATEST

Bristol-Myers Squibb (BMY) earnings: Q3 results beat amid strong product sales

Driven by the strong sales of leading products, earnings of Bristol-Myers Squibb (NYSE: BMY) increased in the third quarter and exceeded the market’s projection. Total revenues rose 6%. The company also provided its revised outlook for fiscal 2019. The stock gained early Thursday, following the announcement.

At $6.0 billion, third-quarter revenues were higher by 6% from the year-ago period. The top line benefited from a 7% sales growth in the US market. International sales rose by 3% during the quarter.

Bristol-Myers Squibb (BMY) earnings: Q3 results beat amid strong product sales

The New York-based pharmaceutical company reported adjusted earnings of $1.17 per share, up from last year’s earnings of $1.09 per share and above Wall Street’s prediction. Net earnings attributable to shareholders climbed to $1.4 billion or $0.83 per share from $1.9 million or $1.16 per share last year.

Related: Bristol-Myers lets go of psoriasis drug to save Celgene merger

Product-wise, sales of anticoagulant Eliquis and Sprycel moved up 22% and 14% respectivley, year-over-year, while sales of melanoma drug Yervoy declined 8%.

“With strong momentum in our R&D and commercial organizations, I am looking forward to the tremendous opportunity when Bristol-Myers Squibb and Celgene come together as one, to deliver innovative medicines and transform patients’ lives ,” said CEO Giovanni Caforio.

The company lowered its guidance for full-year unadjusted earnings to $3.46 -$3.56 per share from the previous outlook of $3.73- $3.83 per share. Meanwhile, it raised the adjusted earnings guidance range to $4.25-$4.35 per share to $4.20-$4.30 per share. Full-year effective tax rate, on unadjusted basis, is expected to be between 13% and 14%.

Also Read:  Pfizer (PFE) raises outlook on hopes of prescription trends recovery and COVID-19 vaccine progress

The company said it is on track to complete the acquisition of biopharma company Celgene. Also, preparations are on for the post-acquisition integration.

Related: Bristol-Myers Q2 2019 Earnings Conference Call Transcript

Earlier this week, Pfizer (NYSE: PFE) reported lower revenues and earnings for the third quarter. The results, however, topped the market’s expectations. The management also revised up the full-year earnings and revenue guidance.

Bristol-Myers’ stock plunged to a six-year low in early July, but bounced back in the following weeks. The shares moved up 15% since the beginning of the year and 10% in the past twelve months.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Novavax (NVAX) stock tumbles despite beating bottom line estimates in Q2

After Novavax (NASDAQ: NVAX) reported its progress on developing the COVID-19 vaccine at the end of February, the shares of the company started trading in double-digits after a long time.

During tough times, Tilray (TLRY) looks overseas to achieve growth targets

Cannabis was recognized as an essential business in several markets when the shutdown came into effect, including Canada and some US states, at a time when its legalization is getting

Eastman Kodak (KODK) swings to a loss in Q2 2020; revenue drops 31%

Eastman Kodak (NYSE: KODK) reported a loss of $5 million on revenue of $213 million in the second quarter of 2020. The company earned $201 million in the prior-year quarter.

One thought on “Bristol-Myers Squibb (BMY) earnings: Q3 results beat amid strong product sales

Comments are closed.

Top